Table 1 Grade 3 to 5 adverse events of special interest in patients aged ≥70 years versus patients aged <70 years in the ATHENA trial (Biganzoli et al. 2012 ) [Permission required for reproduction]
Age <70 years (n = 2,076), % | Age ≥70 years (n = 175), % | |||
|---|---|---|---|---|
On treatment | Entire study period | On treatment | Entire study period | |
Hypertension | 3.2 | 4.2 | 5.1 | 6.9 |
Grade 3 | 3.1 | 4.0 | 4.6 | 6.3 |
Grade 4 | <0.1 | 0.1 | 0.6 | 0.6 |
ATE/VTE | 1.2 | 3.3 | 0.6 | 2.9 |
Grade 3 | 1.2 | 2.4 | 0.6 | 0.6 |
Grade 4 | 0 | 0.7 | 0 | 1.7 |
Grade 5 | 0 | 0.2 | 0 | 0.6 |
Proteinuria | 1.0 | 1.5 | 2.3 | 4.0 |
Grade 3 | 1.0 | 1.4 | 2.3 | 2.9 |
Grade 4 | 0 | 0.1 | 0 | 1.1 |
Other hemorrhage | 0.3 | 1.4 | 1.1 | 1.1 |
Grade 3 | 0.2 | 1.1 | 1.1 | 1.1 |
Grade 4 | <0.1 | 0.2 | 0 | 0 |
Grade 5 | 0 | 0.1 | 0 | 0 |
Wound healing complications | 0.3 | 0.6 | 0.6 | 1.1 |
Grade 3 | 0.2 | 0.3 | 0 | 0.6 |
Grade 4 | 0.1 | 0.2 | 0.6 | 0.6 |
Congestive heart failure | 0.1 | 0.4 | 0 | 0.6 |
Grade 3 | 0.1 | 0.3 | 0 | 0 |
Grade 4 | <0.1 | <0.1 | 0 | 0 |
Grade 5 | 0 | 0.1 | 0 | 0.6 |
Gastrointestinal perforation | 0 | 0.3 | 0 | 0 |
Grade 3 | 0 | 0.1 | 0 | 0 |
Grade 4 | 0 | <0.1 | 0 | 0 |
Grade 5 | 0 | 0.1 | 0 | 0 |
Fistulae | 0 | 0.1 | 0 | 0 |
Grade 3 | 0 | 0.1 | 0 | 0 |
CNS bleeding | 0 | <0.1 | 0 | 0 |
Grade 5 | 0 | <0.1 | 0 | 0 |